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• Coronary artery disease (CAD) causes local 
hypoxia due to reduced blood flow
• Hypoxic conditions are known to induce vascular 
endothelial growth factor (VEGF) production, a key 
contributor to angiogenesis
• The purpose of this study was to determine the 
potential of VEGF as a marker of myocardial 
stress in subjects with CAD undergoing coronary 
artery bypass grafting (CABG) surgery 
Introduction
• Research was performed in accordance with study 
protocols approved by Maine Medical Center 
Institutional Review Board
• The study cohort consisted of plasma samples 
from 73 patients undergoing CABG surgery at 
Maine Medical Center (MMC) in Portland, ME
• Plasma samples were collected prior to operation 
(pre-op), during surgery, and 4-8, 24 and 96 hours 
following surgery
• VEGF concentration was determined using a 
DuoSet enzyme-linked immunosorbent assay 
(ELISA) kit (R&D Systems, sensitivity range 
31.3-2000 pg/mL)
• Undetectable levels of VEGF (<31.3 pg/mL) were 
assigned a concentration equal to one-half of the 
lowest calibration point (15.6 pg/mL)
• All statistical analyses were performed in 
GraphPad Prism and a p-value <0.05 was 
considered statistically significant
Methods
Conclusions
• Plasma levels of VEGF are characterized by 
interindividual variability
• Individual VEGF expression appears to vary 
in response to CABG surgery
• CABG surgery did not induce changes in the 
level of circulating VEGF, limiting its potential 
use as a biomarker of cardiometabolic stress 
in CABG patients
Acknowledgements
• Maine Economic Improvement Fund in support of 
T. Jackson
• The MMCRI-USM internship program
Teaka Jackson1,2, Sarah M. Peterson3, Amanda J. Favreau-Lessard1, Joanne Burgess4, Susan Bosworth-Farrell4, 
Robert S. Kramer1,4, Sergey Ryzhov1, Douglas B. Sawyer1,4, Michael P. Robich1,4
Potential of vascular endothelial growth factor as a biomarker of coronary artery 
disease in subjects undergoing CABG surgery
Affiliations
1Maine Medical Center Research Institute, Scarborough, ME
2University of Southern Maine, Portland, ME
3Idexx Laboratories, Inc., Westbrook, ME
4Maine Medical Center, Portland, ME
Figure 3. VEGF levels do not differ between time 
points analyzed
VEGF expression for the 16 subjects with detectable 
VEGF levels was subjected to Friedman’s test and Dunn’s 
multiple comparisons test to determine statistical 
significance. Analysis incorporated 11 subjects due to 
missing data at one or more time points for n=5 subjects. 
We did not observe any significant changes in VEGF 
expression across the five time points tested.
Figure 4. Representative data demonstrating 
different changes in VEGF expression following 
surgery
VEGF expression in response to CABG surgery differed 
within the study cohort. Although some individuals 
showed no changes following surgery, others were 
characterized by dynamic changes in VEGF expression. 
These changes included a decrease, an increase, or an 
increase followed by a decrease in VEGF expression. 
Figure 2. Subject expression of VEGF at pre-
operative time point
The majority of patients (69.7%) did not have detectable 
levels of VEGF at any time point (red). VEGF protein was 
characterized by interindividual variability (CQD=34%). 
Therefore, subjects with detectable levels of VEGF at the 
pre-operative time point (black) were considered VEGF 
expressors and subjected to further statistical analysis. 
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Hypothesis
Due to local hypoxic conditions during surgery, we hypothesize that circulating VEGF levels 
increase immediately following CABG surgery. However, at time points following surgery, we expect 
a decrease in VEGF, indicating successful revascularization.
Table 1. Demographic data of VEGF 
expressors is not significantly different from 
those with undetectable levels
Future Directions
• Determine Hypoxic Inducible Factor 1 (a 
transcription factor for VEGF) expression by ELISA
• Investigate the biological activity of VEGF in CAD 
patients
• Examine potential relationships with cytokine, and 
clinical data and outcomes
• Understand if patient subpopulations (diabetes, 
heart failure) have varying VEGF levels and if they 
are impacted clinically
Blood collection, plasma preparation, 
collection of clinical data
ELISA
Results
Study Subject Demographics VEGF 
Expressors
Undetectable p‐value
Number of subjects 16 50
Age* 66 ± 10 63 ± 11 0.47‡
Female† 5 (31%) 20 (40%)
0.57§
Male† 11 (69%) 30 (60%)
BMI* 32.3 ± 7.5 29.6 ± 5.8 0.18‡
Aortic cross clamp time (min)* 85 ± 28 82 ± 30 0.55‡
CPB time (min)* 100 ± 34 105 ± 35 0.60‡
Smoking history† 8 (50%) 36 (72%) 0.13§
HbA1c %* 7.0 ± 1.9 6.7 ± 1.8 0.67‡
EF<50%† 2 (13%) 12 (24%) 0.49§
*mean ± SD, †number of research subjects (%), BMI=body mass index, CPB=cardiopulmonary 
bypass, HbA1c=hemoglobin A1c, EF=ejection fraction
‡Mann‐Whitney t‐test, §Fisher exact test
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Figure 1. Determining concentration of VEGF in 
plasma samples
Left Representative VEGF ELISA plate. Lane 1 
contains standard concentrations, and lanes 2 through 
6 contain subject plasma samples
Right Standards were plotted in GraphPad Prism and 
plasma VEGF concentrations were back-calculated 
based on the calibration curve
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